Stocks › EBS
Emergent BioSolutions Inc.
EBS·NYSE·
United States·USD
$5.05
-0.10 (-1.94%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
EBS
Emergent BioSolutions Inc. · NYSE
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
EBSS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of EBS by members of U.S. Congress · 13 on record
Whale Activity
Position changes in EBS reported for 2026-09-30 by 223 institutional filers
- Increased69
- New31
- Held26
- Decreased55
- Closed37
- No prior filing5
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 5.2M | $34.1M | increased |
| AMERICAN CENTURY COMPANIES INC | 3.3M | $21.9M | increased |
| STATE STREET CORP | 2.7M | $17.9M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 2.6M | $16.9M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $14.3M | decreased |
| LSV ASSET MANAGEMENT | 2.0M | $13.1M | — |
| ACADIAN ASSET MANAGEMENT LLC | 1.9M | $12.8M | increased |
| MILLENNIUM MANAGEMENT LLC | 1.9M | $12.4M | increased |
| OAK HILL ADVISORS LP | 1.5M | $10.0M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3M | $8.4M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.2M | $7.8M | increased |
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 1.1M | $7.5M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by EBS insiders, by quarter · Form 4
Recent Insider Transactions
2,962 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| DeGolyer Donald WDirector · Director | Sale | −17.8K | $7.09 | $126K | Oct 7, 2026 | Form 4 ↗ |
| Williams Paul AnthonySVP, Products Business | Sale | −3,000 | $6.53 | $20K | Oct 1, 2026 | Form 4 ↗ |
| Williams Paul AnthonySVP, Products Business | Sale | −3,000 | $8.40 | $25K | Jul 1, 2026 | Form 4 ↗ |
| Hartzel WilliamSVP, Bioservices | Tax withholding | −1,741 | $8.00 | $14K | Jun 8, 2026 | Form 4 ↗ |
| Williams Paul AnthonySVP, Products Business | Tax withholding | −694 | $8.00 | $6K | Jun 8, 2026 | Form 4 ↗ |
| Glessner ColeenEVP, Quality & Ethics, and CPL | Tax withholding | −2,018 | $8.00 | $16K | Jun 8, 2026 | Form 4 ↗ |
| LINDAHL RICHARD SEVP, Chief Financial Officer | Tax withholding | −3,964 | $8.00 | $32K | Jun 8, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Sale | −1,057 | $8.97 | $9K | May 1, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Sale | −16.1K | $8.36 | $135K | May 1, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Sale | −954 | $8.96 | $9K | May 1, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Sale | −14.5K | $8.36 | $121K | May 1, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Sale | −980 | $8.94 | $9K | May 1, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Sale | −12.8K | $8.36 | $107K | May 1, 2026 | Form 4 ↗ |
| Zoon Kathryn CDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| DeGolyer Donald WDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Dayal Sujata TyagiDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Fowler Neal FranklinDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| White Marvin LDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Harsanyi ZsoltChairman · Director | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
| Richard RonaldDirector | Grant / award | +25.3K | $0.00 | $0 | Apr 30, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding EBS · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 2.8M | $17.0M | 0.05% | Aug 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST | 1.7M | $14.3M | 0.13% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.6M | $13.0M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.4M | $11.6M | 0.01% | Jun 30, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 705.6K | $5.1M | 0.03% | Jul 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 592.8K | $5.0M | 0.01% | Jun 30, 2026 |
| Federated Hermes MDT Small Cap Core Fund Federated Hermes MDT Series | 630.3K | $4.6M | 0.20% | Jul 31, 2026 |
| VANGUARD STRATEGIC EQUITY FUND VANGUARD HORIZON FUNDS | 528.6K | $4.4M | 0.04% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF iShares Trust | 502.4K | $4.2M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 569.1K | $4.1M | 0.01% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list EBS's shares (CUSIP 29089Q105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Oak Hill Advisors LPSCHEDULE 13G/A · passive (13G) · 4.0M shares7.5%
Nov 16, 2026 · ↗ - Stowers Institute for Medical ResearchSCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
Nov 16, 2026 · ↗ - American Century Companies, Inc.SCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
Nov 16, 2026 · ↗ - American Century Investment Management, Inc.SCHEDULE 13G/A · passive (13G) · 3.3M shares6.5%
Nov 16, 2026 · ↗ - American Century ETF TrustSCHEDULE 13G/A · passive (13G) · 3.2M shares6.2%
Nov 16, 2026 · ↗ - Vanguard Capital ManagementSCHEDULE 13G/A · passive (13G) · 2.5M shares4.9%
Jul 31, 2026 · ↗ - BlackRock, Inc.SCHEDULE 13G/A · passive (13G) · 4.7M shares9.0%
Jul 28, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming emergent biosolutions as client
- CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q3 · BUD, DIS, HCR, HOM$60K
Filing ↗ - THE NICKLES GROUP, LLCEMERGENT BIOSOLUTIONS · 2026 Q3 · BUD, HCR, DEF$25K
Filing ↗ - CAPITOL COUNSEL LLCEMERGENT BIOSOLUTIONS · 2026 Q3 · HCR$50K
Filing ↗ - EMERGENT BIOSOLUTIONS INC.EMERGENT BIOSOLUTIONS INC · 2026 Q3 · HOM, DIS, BUD, HCR$450K
Filing ↗ - CGCN GROUP, LLCEMERGENT BIOSOLUTIONS INC. · 2026 Q2 · DIS, HCR, HOM, BUD$70K
Filing ↗
Government Contracts
Federal awards to emergent biosolutions · USAspending
$320.9MAwarded · 1 contract on record
- Department of Health and Human ServicesBOTULISM ANTITOXIN$320.9M
Sep 30, 2019 · ↗
U.S. Patents
Recent USPTO applications naming Emergent BioSolutions Inc.
No USPTO patent applications found for Emergent BioSolutions Inc..
Annual Financials
From EBS's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $742.9M | $1.04B | $1.05B | $1.12B | $1.77B |
| Operating income | $100.1M | -$108.7M | -$726.4M | -$170.0M | $341.4M |
| Net income | $52.6M | -$190.6M | -$760.5M | -$211.6M | $219.5M |
| Diluted EPS | $0.93 | -$3.60 | -$14.85 | -$4.22 | $4.06 |
| Operating cash flow | $170.6M | $58.7M | -$206.3M | -$34.1M | $320.2M |
| Cash and equivalents | $205.4M | $99.5M | $111.7M | $642.6M | $576.1M |
| Total assets | $1.32B | $1.39B | $1.82B | $3.17B | $2.96B |
| Total liabilities | $796.0M | $906.9M | $1.17B | $1.78B | $1.34B |
| Shareholders' equity | $522.6M | $482.8M | $649.3M | $1.39B | $1.61B |
As Emergent BioSolutions Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 27, 2026 ↗
Stock Splits
Every split and reverse split in the price history
No stock splits in EBS's price history.
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 8.01, 9.01Other eventsNov 4, 2026
EDGAR ↗ - 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 2, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeOct 16, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 14, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 1, 2026
EDGAR ↗ - 8-K · Items 2.02, 2.05, 5.02, 7.01, 9.01Results of operations · Exit or disposal costs · Officer / director changeAug 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 29, 2026
EDGAR ↗
About Emergent BioSolutions Inc.
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersGAITHERSBURG, MD
IncorporatedDE
SEC CIK0001367644 ↗



